Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
12.85
+0.37 (2.96%)
Nov 28, 2025, 4:00 PM EST - Market closed
Jade Biosciences Employees
Jade Biosciences had 30 employees as of December 31, 2024.
Employees
30
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,131,933
Market Cap
591.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JBIO News
- 15 days ago - Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 20 days ago - Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
- 25 days ago - Jade Biosciences to Participate in Upcoming Conferences - GlobeNewsWire
- 6 weeks ago - Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
- 7 weeks ago - Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases - GlobeNewsWire
- 7 weeks ago - Jade Biosciences Announces $135 Million Private Placement - GlobeNewsWire
- 3 months ago - Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy - GlobeNewsWire
- 3 months ago - Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire